Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study
Kim M. Pabst(West German Heart and Vascular Center Essen), Wolfgang P. Fendler(Essen University Hospital), Josefine Rawitzer(Essen University Hospital), Lukas Kessler(German Cancer Research Center), Stefano Fanti(Azienda USL di Bologna), Claudia Kesch(Essen University Hospital), Boris Hadaschik(Essen University Hospital), Rainer Hamacher(Essen University Hospital), Ken Herrmann(Essen University Hospital), Luisa S. Bodensieck(Essen University Hospital), Riccardo Mei(Azienda USL di Bologna), Katharina Lückerath(Essen University Hospital), Kelsey L. Pomykala
Cited by 18
Related Papers
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
|Neuroendocrinology|2017|495
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
|European Urology|2019|191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
|Annals of Oncology|2019|182
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
|European Journal of Cancer|2023|156
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
|Clinical Cancer Research|2022|145